Cancer patients who receive chest radiation should be screened for heart disease every 5-10 years, according to the European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology (ESC) and the American Society of Echocardiography (ASE).

czytaj więcej

The U. S. Food and Drug Administration approved afatinib (Gilotrif tablets, Boehringer Ingelheim Pharmaceuticals, Inc.), for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.

czytaj więcej

New research published in The Lancet Oncology shows that although women who survive childhood cancer are at an increased risk of infertility, if they have clinical infertility they still have a good likelihood of going on to conceive; about two thirds of them get pregnant, a rate similar to the rate of pregnancy seen in non-cancer survivors with clinical infertility.

czytaj więcej

A new analysis has found that among patients with chronic lymphocytic leukaemia, African Americans more commonly present with advanced disease, and they tend to have shorter survival times than Caucasians despite receiving the same care.

Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the results suggest that biological factors may account for some racial disparities in cancer survival.

czytaj więcej

A second large, prospective study by scientists at Fred Hutchinson Cancer Research Center has confirmed the link between high blood concentrations of omega-3 fatty acids and an increased risk of prostate cancer.

Published in the Journal of the National Cancer Institute, the latest findings indicate that high concentrations of EPA, DPA and DHA – the three anti-inflammatory and metabolically related fatty acids derived from fatty fish and fish-oil supplements – are associated with a 71 percent increased risk of high-grade prostate cancer.

czytaj więcej

Colorectal cancer survivors face an increased risk of developing subsequent cancers, particularly second colorectal cancers and small intestinal cancers. That is the conclusion of a new study published online in CANCER, a peer-reviewed journal of the American Cancer Society. The findings may help in the development of screening guidelines for patients with a history of colorectal cancer.

czytaj więcej

New evidence suggests that using advanced genetics technologies to monitor for remaining cancer cells after treatment may soon become an effective tool to inform treatment decisions and ultimately predict patient outcomes for patients with a particularly aggressive form of acute lymphocytic leukemia (ALL). Study results were published online today in Blood, the Journal of the American Society of Hematology (ASH)

czytaj więcej

Melbourne researchers have discovered that anti-cancer compounds currently in clinical trials for some types of leukaemia could offer hope for treating the most common type of breast cancer. 

The researchers, from the Walter and Eliza Hall Institute, found that the compounds, called BH3-mimetics, were effective in treating aggressive oestrogen receptor-positive (ER-positive) breast cancers when combined with the breast cancer drug tamoxifen in preclinical models. Approximately 70 per cent of breast cancers are ER-positive.

czytaj więcej

For patients with advanced gastric cancer, treatment with chemotherapy after surgery can reduce the risk of cancer related death by 34% over five years compared to surgery alone, researchers said at the 15th ESMO World Congress in Gastrointestinal Cancer.

czytaj więcej

ARIAD Pharmaceuticals today announced that the European Commission (EC) has granted a marketing authorization for ponatinib as an orphan medicinal product for two indications:

1. The treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation, and
2. The treatment of adult patients with Philadelphia-chromosome positive acute lymphoblastic leukaemia (Ph ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.

czytaj więcej